Thank you for participating!

Thank you to all who contributed to the National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning Forum. Ultimately, over 1,000 ideas were submitted, with more than 42,000 votes. This remarkable response exceeded expectations and provided a wealth of ideas to draw upon as NHLBI moves forward. Please visit the NHLBI Strategic Visioning page to find out more about the NHLBI Strategic Visioning process.


Welcome to the National Heart, Lung, and Blood Institute (NHLBI) Strategic Visioning Forum. The Institute is gathering ideas for the most compelling scientific priorities in the four NHLBI Strategic Goals to address over the next decade.

(@rjjones) kudos icon +

Goal 3: Advance Translational Research

Allogeneic transplantation as a safe and universally available therapeutic strategy for treating non-malignant blood diseases

Can new advances in allogeneic blood or marrow transplantation (BMT) make the procedure a safe and universally available therapeutic strategy for treating non-malignant blood and immune disorders such as sickle cell anemia, thalassemia, aplastic anemia, and severe combined immune deficiency?

Voting

164 net votes
214 up votes
50 down votes
Active
(@collerb) kudos icon +

Goal 2: Reduce Human Disease

Close the gap: Why do men die of cardiovascular disease (CVD) at an earlier age than women?

Despite evidence that women face challenges in receiving optimal CVD care, data show that men die at an earlier age than women of CVD. This health disparity remains unexplained and there are no specific interventions to address it.

Voting

2 net votes
3 up votes
1 down votes
Active
(@bldbuddy) kudos icon +

Goal 2: Reduce Human Disease

How should platelet (PLT) transfusions be used to treat active bleeding?

Multiple randomized controlled trials have been performed to evaluate the use of prophylactic PLT transfusions in non-bleeding, thrombocytopenic hematology-oncology patients. However no high-quality data exist to guide PLT transfusions in actively bleeding patients inclduing pediatric and adult medical and surgical patients. After hematology-oncology patients, cardiac surgery patients are the next largest group of PLT... more »

Voting

30 net votes
44 up votes
14 down votes
Active
(@nadkarni) kudos icon +

Goal 3: Advance Translational Research

What is the optimal way to improve cardiac arrest resuscitation?

Sudden Death from cardiac arrest and gaps in knowledge of emergency cardiovascular care are the #1 killer of more than 400,000 Americans each year. This epidemic of death and disability is largely ignored and underfunded by NIH and all funding agencies and kills more than HIV, Cancer, Diabetes, and infectious diseases. There is no national registry of cardiac arrest, no mandatory reporting, and poor funding for both fundamental,... more »

Voting

19 net votes
37 up votes
18 down votes
Active
(@nhlbiforumadministrator1) kudos icon +

Goal 2: Reduce Human Disease

Innovations in Red Cell Transfusion in Sickle Cell Disease

Challenges that need to be overcome in blood transfusion, especially in SCD, include:
a. Adopting molecular genotyping as the standard in blood transfusion therapy.
b. Advancing new generation, anti-oxidant hemoglobin-based oxygen carriers (HBOCs) for use in emergencies such as trauma, stroke, acute hemolysis, and in transfusion in SCD and related disorders. In SCD, HBOCs have the capacity to not only serve as substitutes... more »

Voting

29 net votes
47 up votes
18 down votes
Active
(@nhlbiforumadministrator) kudos icon +

Goal 2: Reduce Human Disease

Clinical trial of AAT augmentation therapy in PI MZ subjects

Although severely alpha-1 antitrypsin deficiency (PI ZZ) individuals are rare, PI MZ subjects comprise approximately 3% of the US population. Mounting evidence suggests that PI MZ is a significant risk factor for COPD. A clinical trial of COPD exacerbation frequency using AAT augmentation therapy in PI MZ subjects with moderate-to-severe COPD could provide a rationale for AAT augmentation therapy (or small molecule neutrophil... more »

Voting

1 net vote
1 up votes
0 down votes
Active
(@xuejunparsons) kudos icon +

Goal 3: Advance Translational Research

Current State of Regenerative Medicine: Moving Stem Cell Research from Animals into Humans for Clinical Trials

Realizing the developmental and therapeutic potential of pluripotent human embryonic stem cell (hESC) derivatives has been hindered by the inefficiency and instability of generating clinically-relevant functional cells from pluripotent cells through conventional uncontrollable and incomplete multi-lineage differentiation.

Voting

-21 net votes
13 up votes
34 down votes
Active
(@golan0) kudos icon +

Goal 2: Reduce Human Disease

Reducing Disparities

NHLBI should continue to support prospective cohort studies, projects, and investigators that evaluate longitudinal outcomes in minority populations where longitudinal data are scarce and difficult to obtain. The resources generated remain invaluable and can be used to conduct crosscutting translational research (i.e. the Jackson Heart Study, Strong Heart Study, and others).

Voting

1 net vote
2 up votes
1 down votes
Active
(@nhlbiforumadministrator) kudos icon +

Goal 4: Develop Workforce and Resources

Loss of the middle years

The challenge I write about is the significant lack of funding for science in NHLBI. There are currently programs to increase the funding of early career investigators and many senior faculty are obtaining continuing renewal.

How will NHLBI keep those in their middle of their career years from dropping out of the biomedical workforce?

Voting

85 net votes
102 up votes
17 down votes
Active